The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Alembic Pharma Q3 results: Net profit rises 25% to Rs 293 crore

    Synopsis

    The company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals said in a regulatory filing.

    Agencies
    Shares of Alembic Pharmaceuticals were trading at Rs 1,055.20 per scrip on the BSE, down 1.39 per cent from its previous close.

    INSIGHTS

    Read Stock Insights by ET for a quick analysis

    Explore Now
    NEW DELHI: Drug firm Alembic Pharmaceuticals on Tuesday reported a 24.92 per cent rise in its consolidated net profit to Rs 292.57 crore for the December quarter mainly on account of robust sales. The company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals said in a regulatory filing.

    The consolidated revenue from operations of the company stood at Rs 1,314.33 crore for the quarter under consideration. It was Rs 1,209.13 crore for the same period a year ago, it added.

    "It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in the current quarter," Alembic Pharmaceuticals Managing Director Pranav Amin said.

    Shares of Alembic Pharmaceuticals were trading at Rs 1,055.20 per scrip on the BSE, down 1.39 per cent from its previous close.
    Join the 4th edition of ETMarkets Global Summit 2021 from 20-22 January and brainstorm with thought leaders of the financial world. Click here to register now!

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Read before you invest. Insights on Alembic Pharmaceuticals Ltd.. Explore Now
    The Economic Times